### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-Estimated average burden 3235-0287 0.5 hours per response..

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Response	es)										
Name and Address of Mazur Leonard L	2. Issuer Name a Citius Pharmac			0 3		5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) C/O CITIUS PHAR GREAT ROAD	3. Date of Earliest 03/30-06:00/20		on (M	Ionth/Day/Yea	r)	-		Other (specify be	low)		
MAYNARD, MA 0	(Street) 01754	4. If Amendment,	Date Origi	nal F	iled(Month/Day/Y		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _ Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)		Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Instr. 8)	v	4. Securities A or Disposed of (Instr. 3, 4 and Amount	(A) or	ed (A)	Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
Common Stock		03/30- 06:00/2016		P		5,000,000		\$ 0.6	5,457,143	D	
Common Stock		03/30- 06:00/2016		J		15,116,746		\$ 0 (1)	20,116,746	D	
Reminder: Report on a	separate line for	r each class of securi	ities beneficially ow	ned directl	Per	sons who re			ne collection of information		1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
4. 5. Number 6. Date Exercisable 7. Title

form displays a currently valid OMB control number.

	(e.g., puts, calls, warrants, options, convertible securities)														
Security	Conversion	3. Transaction Date (Month/Day/Year)	Execution Date, if	Code	of Derivative		i		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s)	Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Warrant to Purchase Common Stock	\$ 0.41 (2)	03/30- 06:00/2016		<u>J(2)</u>		0 (2)		(2)	(2)	Common Stock	0 (2)	\$ 0 (2)	3,594,217 (3)	D	
Warrant to Purchase Common Stock	\$ 0.66 (4)	03/30- 06:00/2016		<u>J(4)</u>		0 (4)		<u>(4)</u>	<u>(4)</u>	Common Stock	0 (4)	\$ 0 (4)	3,668,978	D	
Warrant to Purchase Common Stock	4	03/30- 06:00/2016		J <u>(5)</u>		0 (5)		(5)	<u>(5)</u>	Common Stock	0 (5)	\$ 0 (5)	4,197,149	D	
Warrant to Purcahse Common Stock	\$ 0.66 (6)	03/30- 06:00/2016		<u>J(6)</u>		0 (6)		<u>(6)</u>	(6)	Common Stock	0 6	\$ 0 (6)	4,244,707	D	
Warrant to Purchase Common Stock		03/30- 06:00/2016		J <u>(7)</u>		0 (7)		<u>(7)</u>	<u>(7)</u>	Common Stock	0 (7)	\$ 0 (7)	4,566,457	D	
Warrant															

to Purchase Common Stock		03/30- 06:00/2016	J <u>(8)</u>	0 (8)	<u>(8)</u>	(8)	Common Stock	0 (8)	\$ 0 (8)	4,866,420	D	
Warrant to Purchase Common Stock		03/30- 06:00/2016	J <u>(9)</u>	0 (9)	(9)	(9)	Common Stock	0 (9)	\$ 0 (9)	5,071,600	D	
Warrant to Purchase Common Stock	\$ 0.5 (10)	03/30- 06:00/2016	<u>J<sup>(10)</sup></u>	0 (10)	<u>(10)</u>	(10)	Common Stock	0 (10)	\$ 0 (10)	5,134,748	D	
Warrant to Purchase Common Stock	(11)	03/30- 06:00/2016	<u>ј(11)</u>	0 (11)	<u>(11)</u>	<u>(11)</u>	Common Stock	0 (11)	\$ 0 (11)	5,406,333	D	

# **Reporting Owners**

P. (1. O. N. (All	Relationships								
Reporting Owner Name / Address	Director	10% Owner	Officer	Other					
Mazur Leonard L C/O CITIUS PHARMACEUTICALS, INC. 63 GREAT ROAD MAYNARD, MA 01754	X								

## **Signatures**

/s/ Leonard Mazur	04/12-06:00/2016
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents shares of the Issuer issued pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of March 30, 2016 by and among the Issuer, Citius LMB Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of the Issuer and Leonard-Meron Biosciences, Inc., a Delaware corporation ("LMB").
- (1) Citius Livib Acquisition Corp., a Delaware corporation and whonly-owned substidiary of the Issuer and Leonard-Meron Biosciences, inc., a Delaware corporation (Livib) Pursuant to the terms of the Merger Agreement, each share of common stock of LMB and each convertible note of LMB was converted into shares of the Issuer's common stock
- On June 12, 2014, the Reporting Person was granted a five-year warrant to purchase 162,500 shares of LMB common stock at an exercise price of \$0.75 per share. Pursuant to the Merger Agreement, the warrant was converted into a warrant to purchase 294,217 shares of the Issuer's common stock at a per share exercise price of \$0.41. The warrant is fully vested and exercisable immediately.
- Includes an option to purchase 3,300,000 shares of the Issuer's common stock at an exercise price of \$0.45 per share granted to the Reporting Person on September 12, 2014

  (3) pursuant to the Issuer's 2014 Stock Incentive Plan. The option was previously reported on a Form 3 filed with the Commission on behalf of the Reporting Person on October 28, 2015 and amended on April 12, 2016.
- On January 8, 2015, the Reporting Person was granted a five-year warrant to purchase 41,292 shares of LMB common stock at an exercise price of \$1.20 per share. Pursuant to the Merger Agreement, the warrant was converted into a warrant to purchase 74,761 shares of the Issuer's common stock at a per share exercise price of \$0.66. The warrant is fully vested and exercisable immediately.
- On August 18, 2015, the Reporting Person was granted a five-year warrant to purchase 291,717 shares of LMB common stock at an exercise price \$0.90 per share. Pursuant to the Merger Agreement, the warrant was converted into a warrant to purchase 528,171 shares of the Issuer's common stock at a per share exercise price of \$0.50. The warrant is fully vested and exercisable immediately.
- On September 30, 2015, the Reporting Person was granted a five-year warrant to purchase 26,267 shares of LMB common stock at an exercise price of \$1.20 per share.

  (6) Pursuant to the Merger Agreement, the warrant was converted into a warrant to purchase 47,558 shares of the Issuer's common stock at a per share exercise price of \$0.66. The warrant is fully vested and exercisable immediately.
- On November 2, 2015, the Reporting Person was granted a five-year warrant to purchase 172,184 shares of LMB common stock at an exercise price of \$0.90 per share.

  (7) Pursuant to the Merger Agreement, the warrant was converted into a warrant to purchase 311,750 shares of the Issuer's common stock at a per share exercise price of \$0.50.
- The warrant is fully vested and exercisable immediately.

  On November 20, 2015, the Reporting Person was granted a five-year warrant to purchase 171,197 shares of LMB common stock at an exercise price of \$0.90 per share.
- (8) Pursuant to the Merger Agreement, the warrant was converted into a warrant to purchase 309,963 shares of the Issuer's common stock at a per share exercise price of \$0.50. The warrant is fully vested and exercisable immediately.
- On January 8, 2016, the Reporting Person was granted a five-year warrant to purchase 113,324 shares of LMB common stock at an exercise price of \$0.90. Pursuant to the (9) Merger Agreement, the warrant was converted into a warrant to purchase 205,180 shares of the Issuer's common stock at a per share exercise price of \$0.50. The warrant is fully vested and exercisable immediately.
- On March 14, 2016, the Reporting Person was granted a five-year warrant to purchase 34,877 shares of LMB common stock at an exercise price of \$0.90 per share. Pursuant to (10) the Merger Agreement, the warrant was converted into a warrant to purchase 63,148 shares of the Issuer's common stock at a per share exercise of \$0.50. The warrant is fully vested and exercisable immediately.
- On March 15, 2016, the Reporting Person was granted a five-year warrant to purchase 150,000 shares of LMB common stock at an exercise price \$0.75 per share. Pursuant to (11) the Merger Agreement, the warrant was converted into a warrant to purchase 271,585 shares of the Issuer's common stock at a per share price of \$0.41. The warrant is fully vested and exercisable immediately.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.